# NW Biotherapeutics (NWBO)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/NWBO/

- Reporting holders: 9
- Reported value: $413.6K
- Shares held by institutions: 2,221,644 of 1,705,637,993 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [COMPASS FINANCIAL MANAGEMENT LLC](https://holderbook.com/funds/2148724-compass-financial-management-llc/) | $227.1K | 1,215,500 | 0.0% | 1 |
| [KELLEHER FINANCIAL ADVISORS](https://holderbook.com/funds/1507971-kelleher-financial-advisors/) | $149.4K | 800,000 | 0.0% | 2 |
| [VSM Wealth Advisory, LLC](https://holderbook.com/funds/2050660-vsm-wealth-advisory-llc/) | $15.1K | 80,574 | 0.0% | 7 |
| [Opus Capital Group, LLC](https://holderbook.com/funds/1330325-opus-capital-group-llc/) | $11.0K | 60,150 | 0.0% | 29 |
| [Ethos Financial Group, LLC](https://holderbook.com/funds/1954242-ethos-financial-group-llc/) | $6.3K | 39,070 | 0.0% | 10 |
| [Williams Jones Wealth Management, LLC.](https://holderbook.com/funds/1788587-williams-jones-wealth-management-llc/) | $4.7K | 25,000 | 0.0% | 28 |
| [Strive Financial Group ,LLC](https://holderbook.com/funds/2090040-strive-financial-group-llc/) | $19 | 100 | 0.0% | 1 |
| [HANTZ FINANCIAL SERVICES, INC.](https://holderbook.com/funds/1071061-hantz-financial-services-inc/) | $0 | 250 | 0.0% | 1 |
| [Coston, McIsaac & Partners](https://holderbook.com/funds/1945037-coston-mcisaac-partners/) | $0 | 1,000 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 9 | $413.6K |
| Q1 2026 | 6 | $83.3K |
| Q4 2025 | 5 | $43.7K |
| Q3 2025 | 7 | $175.2K |
| Q2 2025 | 7 | $173.5K |
| Q1 2025 | 7 | $160.2K |
| Q4 2024 | 9 | $196.4K |
| Q3 2024 | 9 | $208.7K |
| Q2 2024 | 11 | $286.2K |
| Q1 2024 | 8 | $303.6K |
| Q4 2023 | 8 | $365.1K |
| Q3 2023 | 9 | $481.9K |